Blood biomarkers are altered in elderly hematological patients exhibiting a mosaic loss of the Y chromosome in bone marrow cells
Abstract Background Mosaic loss of the Y chromosome (LOY) is a frequent somatic alteration observed in aging males, linked to clonal hematopoiesis and elevated risks of hematologic malignancies. However, the direct physiological implications of LOY in elderly patients with hematologic disorders rema...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14584-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849333211573780480 |
|---|---|
| author | Lin Liu Liangshun You Huan Xu Lu Wang Shuqi Zhao Hongyan Tong Jie Jin |
| author_facet | Lin Liu Liangshun You Huan Xu Lu Wang Shuqi Zhao Hongyan Tong Jie Jin |
| author_sort | Lin Liu |
| collection | DOAJ |
| description | Abstract Background Mosaic loss of the Y chromosome (LOY) is a frequent somatic alteration observed in aging males, linked to clonal hematopoiesis and elevated risks of hematologic malignancies. However, the direct physiological implications of LOY in elderly patients with hematologic disorders remain unclear. We investigated blood biomarker changes associated with LOY in elderly male patients with hematologic malignancies. Methods We retrospectively analyzed 196 elderly male patients (median age, 71 years) with LOY detected via bone marrow karyotyping (2017–2022). Participants were stratified into four groups: no disease (n = 22); acute myelogenous leukemia, myelodysplastic syndrome (including refractory anemia [RA], refractory anemia with excess blasts [RAEB], and RAEB in transformation [RAEB-T]), chronic myelomonocytic leukemia (CMML) (AML/MDS group, n = 52); multiple myeloma (MM, n = 37); and chronic lymphocytic leukemia (CLL), Hodgkin’s lymphoma (HL), and non-Hodgkin’s lymphoma (NHL) (CLL/lymphoma group, n = 85). Controls (n = 120) exhibited normal 46,XY karyotypes. Blood markers (n = 22)—including blood cell counts, cytokines, immunoglobulins, and thyroid hormones—were assessed using non-parametric tests and multivariate regression analysis. Results LOY was detected in 4% of patients (3% pure LOY, 1% LOY with additional abnormalities). AML/MDS patients with LOY were younger (median 68.5 vs. 75.5 years in no-disease, p = 0.004) and exhibited higher LOY burden (60% vs. 33% in CLL/lymphoma, p < 0.001). Multivariate analysis revealed age as an independent risk factor for AML/MDS (p = 0.002), while LOY burden specifically correlated with CLL/lymphoma (p = 0.012). Distinct biomarker profiles emerged: LOY-positive AML/MDS patients showed reduced hemoglobin, platelets, and cytokines (e.g., reduced interleukin-2, interferon-gamma) versus controls (p < 0.05), whereas CLL/lymphoma cases correlated with decreased immunoglobulins (IgM) and cytokines (e.g., interleukin-4, interleukin-17 A). Notably, individuals without hematologic disease exhibited stable biomarker profiles irrespective of LOY status, suggesting context-dependent effects of LOY. A high LOY burden (≥ 75%) was associated with cytopenias in AML/MDS, characterized by decreased white blood cell (WBC) count, neutrophil count (NEC), and platelet (PLT) count (p < 0.05). Conclusion LOY exhibits disease-specific associations with immune-metabolic dysregulation, particularly in AML/MDS and CLL/lymphoma. Its varying burden and biomarker profiles suggest potential utility in risk stratification, warranting further prospective validation. |
| format | Article |
| id | doaj-art-6aeddcdd86774e3bba7ecf859a1cf0e8 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-6aeddcdd86774e3bba7ecf859a1cf0e82025-08-20T03:45:56ZengBMCBMC Cancer1471-24072025-07-0125111010.1186/s12885-025-14584-0Blood biomarkers are altered in elderly hematological patients exhibiting a mosaic loss of the Y chromosome in bone marrow cellsLin Liu0Liangshun You1Huan Xu2Lu Wang3Shuqi Zhao4Hongyan Tong5Jie Jin6Department of Hematology, the First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of MedicineAbstract Background Mosaic loss of the Y chromosome (LOY) is a frequent somatic alteration observed in aging males, linked to clonal hematopoiesis and elevated risks of hematologic malignancies. However, the direct physiological implications of LOY in elderly patients with hematologic disorders remain unclear. We investigated blood biomarker changes associated with LOY in elderly male patients with hematologic malignancies. Methods We retrospectively analyzed 196 elderly male patients (median age, 71 years) with LOY detected via bone marrow karyotyping (2017–2022). Participants were stratified into four groups: no disease (n = 22); acute myelogenous leukemia, myelodysplastic syndrome (including refractory anemia [RA], refractory anemia with excess blasts [RAEB], and RAEB in transformation [RAEB-T]), chronic myelomonocytic leukemia (CMML) (AML/MDS group, n = 52); multiple myeloma (MM, n = 37); and chronic lymphocytic leukemia (CLL), Hodgkin’s lymphoma (HL), and non-Hodgkin’s lymphoma (NHL) (CLL/lymphoma group, n = 85). Controls (n = 120) exhibited normal 46,XY karyotypes. Blood markers (n = 22)—including blood cell counts, cytokines, immunoglobulins, and thyroid hormones—were assessed using non-parametric tests and multivariate regression analysis. Results LOY was detected in 4% of patients (3% pure LOY, 1% LOY with additional abnormalities). AML/MDS patients with LOY were younger (median 68.5 vs. 75.5 years in no-disease, p = 0.004) and exhibited higher LOY burden (60% vs. 33% in CLL/lymphoma, p < 0.001). Multivariate analysis revealed age as an independent risk factor for AML/MDS (p = 0.002), while LOY burden specifically correlated with CLL/lymphoma (p = 0.012). Distinct biomarker profiles emerged: LOY-positive AML/MDS patients showed reduced hemoglobin, platelets, and cytokines (e.g., reduced interleukin-2, interferon-gamma) versus controls (p < 0.05), whereas CLL/lymphoma cases correlated with decreased immunoglobulins (IgM) and cytokines (e.g., interleukin-4, interleukin-17 A). Notably, individuals without hematologic disease exhibited stable biomarker profiles irrespective of LOY status, suggesting context-dependent effects of LOY. A high LOY burden (≥ 75%) was associated with cytopenias in AML/MDS, characterized by decreased white blood cell (WBC) count, neutrophil count (NEC), and platelet (PLT) count (p < 0.05). Conclusion LOY exhibits disease-specific associations with immune-metabolic dysregulation, particularly in AML/MDS and CLL/lymphoma. Its varying burden and biomarker profiles suggest potential utility in risk stratification, warranting further prospective validation.https://doi.org/10.1186/s12885-025-14584-0Mosaic loss of Y chromosomeHematologic malignanciesElderly patientsClonal hematopoiesisBiomarkers |
| spellingShingle | Lin Liu Liangshun You Huan Xu Lu Wang Shuqi Zhao Hongyan Tong Jie Jin Blood biomarkers are altered in elderly hematological patients exhibiting a mosaic loss of the Y chromosome in bone marrow cells BMC Cancer Mosaic loss of Y chromosome Hematologic malignancies Elderly patients Clonal hematopoiesis Biomarkers |
| title | Blood biomarkers are altered in elderly hematological patients exhibiting a mosaic loss of the Y chromosome in bone marrow cells |
| title_full | Blood biomarkers are altered in elderly hematological patients exhibiting a mosaic loss of the Y chromosome in bone marrow cells |
| title_fullStr | Blood biomarkers are altered in elderly hematological patients exhibiting a mosaic loss of the Y chromosome in bone marrow cells |
| title_full_unstemmed | Blood biomarkers are altered in elderly hematological patients exhibiting a mosaic loss of the Y chromosome in bone marrow cells |
| title_short | Blood biomarkers are altered in elderly hematological patients exhibiting a mosaic loss of the Y chromosome in bone marrow cells |
| title_sort | blood biomarkers are altered in elderly hematological patients exhibiting a mosaic loss of the y chromosome in bone marrow cells |
| topic | Mosaic loss of Y chromosome Hematologic malignancies Elderly patients Clonal hematopoiesis Biomarkers |
| url | https://doi.org/10.1186/s12885-025-14584-0 |
| work_keys_str_mv | AT linliu bloodbiomarkersarealteredinelderlyhematologicalpatientsexhibitingamosaiclossoftheychromosomeinbonemarrowcells AT liangshunyou bloodbiomarkersarealteredinelderlyhematologicalpatientsexhibitingamosaiclossoftheychromosomeinbonemarrowcells AT huanxu bloodbiomarkersarealteredinelderlyhematologicalpatientsexhibitingamosaiclossoftheychromosomeinbonemarrowcells AT luwang bloodbiomarkersarealteredinelderlyhematologicalpatientsexhibitingamosaiclossoftheychromosomeinbonemarrowcells AT shuqizhao bloodbiomarkersarealteredinelderlyhematologicalpatientsexhibitingamosaiclossoftheychromosomeinbonemarrowcells AT hongyantong bloodbiomarkersarealteredinelderlyhematologicalpatientsexhibitingamosaiclossoftheychromosomeinbonemarrowcells AT jiejin bloodbiomarkersarealteredinelderlyhematologicalpatientsexhibitingamosaiclossoftheychromosomeinbonemarrowcells |